H
1.39
0.00 (0.00%)
| Previous Close | 1.39 |
| Open | 1.40 |
| Volume | 1,825,444 |
| Avg. Volume (3M) | 2,222,385 |
| Market Cap | 1,009,326,272 |
| Price / Earnings (Forward) | 125.00 |
| Price / Sales | 0.530 |
| Price / Book | 0.980 |
| 52 Weeks Range | |
| Earnings Date | 20 Feb 2025 |
| Profit Margin | -1.27% |
| Operating Margin (TTM) | -1.43% |
| Diluted EPS (TTM) | -0.960 |
| Quarterly Revenue Growth (YOY) | 6.70% |
| Total Debt/Equity (MRQ) | 136.23% |
| Current Ratio (MRQ) | 1.29 |
| Operating Cash Flow (TTM) | 338.50 M |
| Levered Free Cash Flow (TTM) | -195.19 M |
| Return on Assets (TTM) | 1.34% |
| Return on Equity (TTM) | -3.08% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (AU) | Mixed | Mixed |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | HEALIUS FPO [HLS] | - | - |
AIStockmoo Score
0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.25 |
|
Healius is Australia’s second-largest pathology provider and third-largest diagnostic imaging provider, though the latter business is set to be sold in early 2025. Pathology and imaging revenue is almost entirely earned via the public health Medicare system. Healius typically earns approximately 75% of revenue from pathology and 25% from diagnostic imaging. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Growth |
| % Held by Insiders | 0.79% |
| % Held by Institutions | 65.28% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |